
Operations Office

Telephone (507) 284-2172



Date: March 31, 2006

To: NCCTG Primary Clinical Research Coordinators

From: Patricia A. Mann
Protocol Development Coordinator

Re: N04C2, An Exploratory, Randomized, Placebo-Controlled Trial of Depot Octreotide (Sandostatin LAR[®] Depot) for Symptomatic Ascites in Cancer Patients

DISCREPANCY BETWEEN SCHEMA AND TREATMENT SECTION (7.1 AND 7.11)

Please note that there is an error in the schema. The initial dose of 100 mcg of octreotide is to be given **ONCE** on day 1 per the treatment schedule. The schema indicates a t.i.d. schedule on day 1 which is incorrect. An addendum is in process to correct this.

Please call or e-mail me at mann.patricia@mayo.edu if you have any questions.